Short Descriptions of Cellectricon


Cellectricon in 85 Words

Cellectricon's unique approach of combining microfluidics engineering with biology has enabled the development of completely new types of miniaturized real time cell-based s creening devices for applications in biotechnology, biomedical research and drug discovery.

The company has successfully launched two products up to date with strong customer validation. Ten out of twelve big pharma companies has already adopted the Dynaflow® System for ion channel drug discovery. The company recently launched their second product line, Cellaxess®, a highly-efficient & easy-to-use electroporation systems for transfection of adherent cells.


Cellectricon in 125 Words

Cellectricon's unique approach of combining microfluidics engineering with biology has enabled the development of completely new types of miniaturized real time cell-based screening devices for applications in biotechnology, biomedical research and drug discovery.

The company has successfully launched two products up to date with strong customer validation. Ten out of twelve big pharma companies has already adopted the Dynaflow® System for ion channel drug discovery. The company recently launched their second product line, Cellaxess®, a highly-efficient & easy-to-use electroporation systems for transfection of adherent cells.

The company has a highly promising product pipeline addressing several high growth markets within cell biology. Cellectricon's product and project portfolio is protected by more than 15 patents and patent applications of which several are first in their respective field.


Cellectricon in 178 Words

Cellectricon captures the emerging paradigm shift in drug discovery towards microfluidic assays and is well positioned to create a market impact as a consequence of maximizing efficiency, data quality, throughput and analytical precision. Cellectricon's unique approach of combining microfluidics engineering with biology has enabled the development of completely new types of miniaturized real time cell-based screening devices for applications in biotechnology, biomedical research and drug discovery.

The products enable productivity increases at high data quality and are protected by more than 15 patents and patent applications. The company has successfully launched two products up to date with strong customer validation. Ten out of twelve big pharma companies has already adopted the first product the Dynaflow® System for ion channel drug discovery. In December 2005 the company launched their second product line, Cellaxess®, highly-efficient & easy-to-use electroporation systems for transfection of adherent cells.

The company has a highly promising product pipeline addressing several high growth markets within cell biology. Future areas include broad cell assay coverage for drug screening and clinical areas such as Cloning, IVF & Gene manipulation.